These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 39402469)
1. Evaluating the efficacy of 8 non-invasive models in predicting MASLD and progression: a prospective study. Yang A; Zhu X; Zhang L; Zhang D; Jin M; Lv G; Ding Y BMC Gastroenterol; 2024 Oct; 24(1):365. PubMed ID: 39402469 [TBL] [Abstract][Full Text] [Related]
2. Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease. Kumada T; Toyoda H; Ogawa S; Gotoh T; Suzuki Y; Sugimoto K; Yoshida Y; Kuroda H; Kamada Y; Sumida Y; Ito T; Akita T; Tanaka J Liver Int; 2024 Jul; 44(7):1700-1714. PubMed ID: 38558221 [TBL] [Abstract][Full Text] [Related]
3. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549 [TBL] [Abstract][Full Text] [Related]
4. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis. Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767 [TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262 [TBL] [Abstract][Full Text] [Related]
6. iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study. Hirooka M; Ogawa S; Koizumi Y; Yoshida Y; Goto T; Yasuda S; Yamahira M; Tamai T; Kuromatsu R; Matsuzaki T; Suehiro T; Kamada Y; Sumida Y; Hiasa Y; Toyoda H; Kumada T J Gastroenterol; 2024 Jun; 59(6):504-514. PubMed ID: 38553657 [TBL] [Abstract][Full Text] [Related]
7. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard. Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596 [TBL] [Abstract][Full Text] [Related]
8. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868 [TBL] [Abstract][Full Text] [Related]
9. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE; J Hepatol; 2024 Aug; 81(2):195-206. PubMed ID: 38548067 [TBL] [Abstract][Full Text] [Related]
10. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971 [TBL] [Abstract][Full Text] [Related]
11. Prospective Comparison of Attenuation Imaging and Controlled Attenuation Parameter for Liver Steatosis Diagnosis in Patients With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes. Dioguardi Burgio M; Castera L; Oufighou M; Rautou PE; Paradis V; Bedossa P; Sartoris R; Ronot M; Bodard S; Garteiser P; Van Beers B; Valla D; Vilgrain V; Correas JM; Clin Gastroenterol Hepatol; 2024 May; 22(5):1005-1013.e27. PubMed ID: 38072287 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of low hepatic fat content in advanced chronic liver disease: MRI-PDFF insights. Nakamura A; Yoshimura T; Ichikawa T; Okuyama K Ann Hepatol; 2024; 29(4):101507. PubMed ID: 38723748 [TBL] [Abstract][Full Text] [Related]
13. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis. Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of proton density fat fraction (PDFF) obtained from a vendor-neutral MRI sequence and MRQuantif software. Orcel T; Chau HT; Turlin B; Chaigneau J; Bannier E; Otal P; Frampas E; Leguen A; Boulic A; Saint-Jalmes H; Aubé C; Boursier J; Bardou-Jacquet E; Gandon Y Eur Radiol; 2023 Dec; 33(12):8999-9009. PubMed ID: 37402003 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference. Wang JH; Ou HY; Yen YH; Chen CH; Lu SN Dig Dis Sci; 2020 May; 65(5):1512-1519. PubMed ID: 31617130 [TBL] [Abstract][Full Text] [Related]
16. Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis. Qi S; Wei X; Zhao J; Wei X; Guo H; Hu J; WuYun Q; Pan CQ; Zhang N; Zhang J J Gastroenterol Hepatol; 2024 Aug; 39(8):1656-1662. PubMed ID: 38686620 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D; J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529 [TBL] [Abstract][Full Text] [Related]
18. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease. Gu Q; Cen L; Lai J; Zhang Z; Pan J; Zhao F; Yu C; Li Y; Chen C; Chen W; Shen Z Eur J Clin Invest; 2021 Feb; 51(2):e13446. PubMed ID: 33128454 [TBL] [Abstract][Full Text] [Related]
19. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863 [TBL] [Abstract][Full Text] [Related]
20. Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease. Wang JH; Ou HY; Yen YH; Hung CH; Lu SN Liver Int; 2023 Sep; 43(9):1901-1908. PubMed ID: 37249034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]